ArticleCell cycle (Georgetown, Tex.)2012
A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies.
Article in Cell cycle (Georgetown, Tex.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer.Cancer cell · 2025Article
- CD32B1, a versatile non-signaling antibody-binding scaffold for enhanced T cell adhesion to tumor stromal cognate antigens.Frontiers in immunology · 2025Article
- Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.Journal for immunotherapy of cancer · 2024Article
- FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab.Frontiers in immunology · 2023Article
- TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy.Medical oncology (Northwood, London, England) · 2022Review
- Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer.Science translational medicine · 2021Article
- OX40 as a novel target for the reversal of immune escape in colorectal cancer.American journal of translational research · 2021Review
- Domain binding and isotype dictate the activity of anti-human OX40 antibodies.Journal for immunotherapy of cancer · 2020Article
- Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.Nature communications · 2019Article
- HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.Journal for immunotherapy of cancer · 2019Article
- Immune Checkpoints as Therapeutic Targets in Autoimmunity.Frontiers in immunology · 2018Review
- A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity.Frontiers in oncology · 2018Article
- Signaling by Antibodies: Recent Progress.Annual review of immunology · 2017Review
- Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.The Journal of biological chemistry · 2016Article
- Article
- Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.Cancer cell · 2016Article
- Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.Journal of immunological methods · 2015Article
- Type I and type II Fc receptors regulate innate and adaptive immunity.Nature immunology · 2014Review
- Inhibitory Fcγ receptor is required for the maintenance of tolerance through distinct mechanisms.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- The function of Fcγ receptors in dendritic cells and macrophages.Nature reviews. Immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comment on: Li F, et al. Proc Natl Acad Sci USA 2012; 109:10966-71.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.